Hesk: A spinoff is one of a few possibles.
Another is where Janssen licence a peptide/peptides for the clinic.
Still another could see other areas of Janssen build collaborations with PYC(refer to the following post):
http://hotcopper.com.au/post_threadview.asp?fid=1&tid=2155899&msgno=10152926#10152926.
I think any of those three possibles would make Phylogica glow.
peace: Seattle Genetics in the ADC space, is attracting bulk business from pharma but they haven't been acquired.
SoT
going intracellular, page-6
-
- There are more pages in this discussion • 75 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
14.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $676.5M | |||
| Open | High | Low | Value | Volume |
| 14.5¢ | 14.5¢ | 13.5¢ | $624.7K | 4.470M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 469075 | 14.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 14.5¢ | 486894 | 4 |
View Market Depth
| Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
| PYC (ASX) Chart |